Addex Therapeutics to Report Q1 2026 Results, Host Call June 25
Addex Therapeutics (ADXN) will release first-quarter 2026 financial results and conduct a conference call at 10:00 EDT on June 25, 2026, with CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev providing a pipeline update.
Addex Therapeutics (ADXN) will report first-quarter 2026 financial results on June 25, 2026, the Geneva-based biopharmaceutical company announced June 22.
CEO Tim Dyer and Mikhail Kalinichev, Head of Translational Science, will host a teleconference and webcast at 16:00 CEST (10:00 EDT) on June 25 to provide a business update and review the company's pipeline of small molecule allosteric modulators for neurological disorders. The company, which trades on both SIX Swiss Exchange and Nasdaq under ticker ADXN, did not disclose specific financial figures or clinical milestones in the announcement.
Continue reading
3 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.